Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Nephros (NEPH) Shares Outstanding (2016 - 2025)

Nephros has reported Shares Outstanding over the past 16 years, most recently at $10.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $10.6 million for Q4 2025, up 0.94% from a year ago — trailing twelve months through Dec 2025 was $10.6 million (up 0.94% YoY), and the annual figure for FY2025 was $10.6 million, up 0.94%.
  • Shares Outstanding for Q4 2025 was $10.6 million at Nephros, roughly flat from $10.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding for NEPH hit a ceiling of $10.6 million in Q4 2025 and a floor of $9.9 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $10.4 million (2022), compared with a mean of $10.4 million.
  • Biggest five-year swings in Shares Outstanding: rose 12.75% in 2021 and later dropped 0.06% in 2023.
  • Nephros' Shares Outstanding stood at $10.2 million in 2021, then rose by 0.97% to $10.3 million in 2022, then increased by 1.98% to $10.5 million in 2023, then grew by 0.41% to $10.5 million in 2024, then rose by 0.94% to $10.6 million in 2025.
  • The last three reported values for Shares Outstanding were $10.6 million (Q4 2025), $10.6 million (Q3 2025), and $10.6 million (Q2 2025) per Business Quant data.